Research ArticleArticle
The CYP2B6*6 Allele Significantly Alters the N-Demethylation of Ketamine Enantiomers In Vitro
Yibai Li, Janet K. Coller, Mark R. Hutchinson, Kathrin Klein, Ulrich M. Zanger, Nathan J. Stanley, Andrew D. Abell and Andrew A. Somogyi
Drug Metabolism and Disposition June 2013, 41 (6) 1264-1272; DOI: https://doi.org/10.1124/dmd.113.051631
Yibai Li
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Janet K. Coller
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Mark R. Hutchinson
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Kathrin Klein
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Ulrich M. Zanger
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Nathan J. Stanley
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Andrew D. Abell
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Andrew A. Somogyi
Discipline of Pharmacology (Y.L., J.K.C., A.A.S.), Discipline of Physiology (M.R.H.), Discipline of Chemistry (A.D.A.), and Centre for Personalised Cancer Medicine (A.A.S.), The University of Adelaide, Adelaide, South Australia, Australia; Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany and University of Tübingen, Tübingen, Germany (K.K., U.M.Z.); and Department of Chemistry, University of Otago, Dunedin, New Zealand (N.J.S.)
Submit a Response to This Article
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
CYP2B6*6 and Ketamine Metabolism
Yibai Li, Janet K. Coller, Mark R. Hutchinson, Kathrin Klein, Ulrich M. Zanger, Nathan J. Stanley, Andrew D. Abell and Andrew A. Somogyi
Drug Metabolism and Disposition June 1, 2013, 41 (6) 1264-1272; DOI: https://doi.org/10.1124/dmd.113.051631
Research ArticleArticle
CYP2B6*6 and Ketamine Metabolism
Yibai Li, Janet K. Coller, Mark R. Hutchinson, Kathrin Klein, Ulrich M. Zanger, Nathan J. Stanley, Andrew D. Abell and Andrew A. Somogyi
Drug Metabolism and Disposition June 1, 2013, 41 (6) 1264-1272; DOI: https://doi.org/10.1124/dmd.113.051631
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement